{"id":3207,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2020-03-12","marketCap":770.306396484375,"name":"Enliven Therapeutics Inc","phone":"17206478519","outstanding":41.209999084472656,"symbol":"ELVN","website":"https://www.enliventherapeutics.com/","industry":"Pharmaceuticals"},"price":18.180025,"year":2024,"month":3,"day":28,"weekday":"Thursday","title":"Corporate Governance Practices of Enliven Therapeutics Inc Stock","date":"2024-03-28","url":"/posts/2024/03/28/ELVN","content":[{"section":"Board Composition","text":"The board of Enliven Therapeutics Inc is composed of highly qualified individuals with diverse backgrounds and expertise. The board includes representatives from various fields, such as pharmaceutical research, finance, and legal. This diverse composition ensures that the board has a wide range of perspectives and knowledge to guide the company effectively."},{"section":"Executive Compensation","text":"Enliven Therapeutics Inc follows a reasonable approach to executive compensation. The company strives to align executive pay with the company's performance and shareholder interests. The compensation packages of executives include a combination of fixed salary, performance-based bonuses, and long-term incentives tied to the company's financial and non-financial goals. This approach promotes accountability and incentivizes executives to drive long-term sustainable growth."},{"section":"Ethical Standards","text":"Enliven Therapeutics Inc maintains high ethical standards in its corporate governance practices. The company has established a code of conduct and ethics that all directors, executives, and employees are expected to adhere to. This code promotes transparency, integrity, and responsible decision-making."},{"section":"Board Independence","text":"Enliven Therapeutics Inc emphasizes the importance of board independence. A majority of the board members are independent directors who do not have any material relationships with the company that could potentially compromise their objectivity. This independence ensures that the board can effectively exercise its oversight responsibilities and act in the best interests of shareholders."},{"section":"Shareholder Engagement","text":"Enliven Therapeutics Inc prioritizes shareholder engagement and communication. The company regularly engages with its shareholders through investor meetings, annual general meetings, and other forums. The company encourages shareholders to actively participate in key decision-making processes and provides transparent and timely information to facilitate informed decision-making."},{"section":"Risk Management","text":"Enliven Therapeutics Inc has a robust risk management framework in place. The board actively monitors and assesses the company's risks and implements effective risk mitigation strategies. The company promotes a strong risk-aware culture throughout the organization by providing comprehensive training and awareness programs to employees."},{"section":"Board Committees","text":"Enliven Therapeutics Inc has established various board committees to strengthen its governance practices. These committees include audit, compensation, and nominating and corporate governance committees. The committees are composed of independent directors and have defined roles and responsibilities to ensure effective oversight and decision-making."},{"section":"Conclusion","text":"Enliven Therapeutics Inc demonstrates a commitment to strong corporate governance practices. The company's board composition, executive compensation, ethical standards, board independence, shareholder engagement, risk management, and board committees contribute to a robust governance framework that aims to protect shareholder interests and promote long-term value creation."}],"tags":["CrossOver21","Long","Pharmaceuticals"],"news":[{"category":"company","date":1711173098,"headline":"Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares","id":126652276,"image":"https://s.yimg.com/ny/api/res/1.2/G9Dw_RBlPuQNdOKos9xHRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD01MjU-/https://media.zenfs.com/en/us.finance.gurufocus/cbeb7284d827278eee1ab3f032d09e04","symbol":"ELVN","publisher":"Yahoo","summary":"In a recent transaction on March 20, 2024, Director Rahul Ballal of Enliven Therapeutics Inc (NASDAQ:ELVN) sold 13,278 shares of the company's stock, according to a SEC Filing.","url":"https://finance.yahoo.com/news/enliven-therapeutics-inc-director-rahul-055138687.html"},{"category":"company","date":1710916260,"headline":"Analystsâ€™ Top Healthcare Picks: Enliven Therapeutics (ELVN), Alphatec Holdings (ATEC)","id":126596359,"image":"","symbol":"ELVN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3406576530"},{"category":"company","date":1710852660,"headline":"Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session","id":126576882,"image":"","symbol":"ELVN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3405320126"},{"category":"company","date":1710851640,"headline":"12 Health Care Stocks Moving In Tuesday's Intraday Session","id":126576978,"image":"","symbol":"ELVN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3405297877"},{"category":"company","date":1710851400,"headline":"Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates","id":126572576,"image":"https://s.yimg.com/ny/api/res/1.2/6rujbgHPosPkFwMUu5ziCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzQ-/https://media.zenfs.com/en/globenewswire.com/460c16185bbaa782f6ab32ce430ea822","symbol":"ELVN","publisher":"Yahoo","summary":"Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026 and through multiple key clinical milestones for ELVN-001 and ELVN-002 Company to host an event with KOLs on April 11, 2024, to discuss initial proof of concept data from a Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) BOULDER, Colo., March 19, 2024 (GLOBE NEWSWIRE)","url":"https://finance.yahoo.com/news/enliven-therapeutics-announces-90-million-123000921.html"},{"category":"company","date":1710849300,"headline":"OTRK, STRC and APM among mid-day movers","id":126575372,"image":"","symbol":"ELVN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3405244891"},{"category":"company","date":1710848280,"headline":"Wall Street Mixed As Tech Stocks Fall, Fed Meeting Begins","id":126574987,"image":"","symbol":"ELVN","publisher":"TalkMarkets","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3405222918"},{"category":"company","date":1710839280,"headline":"National CineMedia Reports Upbeat Results, Joins Nordstrom, Core \u0026 Main And Other Big Stocks Moving Higher On Tuesday","id":126574098,"image":"","symbol":"ELVN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3405031636"},{"category":"company","date":1710838980,"headline":"Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers","id":126574624,"image":"","symbol":"ELVN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3405025373"},{"category":"company","date":1710836640,"headline":"Enliven Therapeutics announces $90M private placement to fund R\u0026D activities","id":126586611,"image":"","symbol":"ELVN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3404976661"},{"category":"company","date":1710835740,"headline":"12 Health Care Stocks Moving In Tuesday's Pre-Market Session","id":126573707,"image":"","symbol":"ELVN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3404959171"},{"category":"company","date":1710835380,"headline":"Enliven Therapeutics Secures $90M for Clinical Research Expansion","id":126586615,"image":"","symbol":"ELVN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3404952668"},{"category":"company","date":1710834060,"headline":"Enliven announces pipeline updates","id":126586616,"image":"","symbol":"ELVN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3404925836"},{"category":"company","date":1710833940,"headline":"Enliven announces $90M private placement financing","id":126586617,"image":"","symbol":"ELVN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3404923775"},{"category":"company","date":1710467760,"headline":"Strong Buy Rating for Enliven Therapeutics Backed by Innovative Drug Candidates and Financial Stability","id":126528540,"image":"","symbol":"ELVN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3399907428"},{"category":"company","date":1710446700,"headline":"Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update","id":126520481,"image":"","symbol":"ELVN","publisher":"Yahoo","summary":"Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024 IND application to evaluate ELVN-002 in combination with trastuzumab in patients with HER2+ metastatic breast cancer and colorectal cancer received U.S. FDA clearance Strong balance sheet, closing the year with $253 million in cash, cash equivalents and marketable securities BOULDER, Colo., March 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therape","url":"https://finance.yahoo.com/news/enliven-therapeutics-reports-fourth-quarter-200500032.html"},{"category":"company","date":1710406560,"headline":"ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023","id":126528541,"image":"","symbol":"ELVN","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3398769049"},{"category":"company","date":1710405960,"headline":"TD Cowen Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)","id":126528542,"image":"","symbol":"ELVN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3398755024"},{"category":"company","date":1710390360,"headline":"Enliven Therapeutics GAAP EPS of -$0.47","id":126507327,"image":"","symbol":"ELVN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3398308235"},{"category":"company","date":1710386580,"headline":"Enliven reports Q4 EPS (47c), consensus (54c)","id":126507328,"image":"","symbol":"ELVN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3398205867"}]}